<SEC-DOCUMENT>0001213900-22-033890.txt : 20220621
<SEC-HEADER>0001213900-22-033890.hdr.sgml : 20220621
<ACCEPTANCE-DATETIME>20220621140731
ACCESSION NUMBER:		0001213900-22-033890
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20220621
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20220621
DATE AS OF CHANGE:		20220621

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABVC BIOPHARMA, INC.
		CENTRAL INDEX KEY:			0001173313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				260014658
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40700
		FILM NUMBER:		221027486

	BUSINESS ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538
		BUSINESS PHONE:		510-668-0881

	MAIL ADDRESS:	
		STREET 1:		44370 OLD WARM SPRINGS BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94538

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	American BriVision (Holding) Corp
		DATE OF NAME CHANGE:	20160111

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METU BRANDS, INC.
		DATE OF NAME CHANGE:	20150908

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ECOLOGY COATINGS, INC.
		DATE OF NAME CHANGE:	20080821
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea161846-8k_abvcbio.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:ABVC="http://abvcpharma.com/20220621">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02B_US%2DGAAP%2D2022 -->
<!-- Field: Set; Name: xdx; ID: xdx_038_ABVC_abvcpharma.com_20220621 -->
<!-- Field: Set; Name: xdx; ID: xdx_040_20220621_20220621 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DEntityCentralIndexKey_0001173313 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2022-06-21to2022-06-21" name="dei:EntityCentralIndexKey">0001173313</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2022-06-21to2022-06-21" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="abvc-20220621.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2022-06-21to2022-06-21">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001173313</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-06-21</xbrli:startDate>
        <xbrli:endDate>2022-06-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Washington,
DC 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
<span id="xdx_90A_edei--DocumentType_c20220621__20220621_z8E7QABV31Ua"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported): <span id="xdx_909_edei--DocumentPeriodEndDate_c20220621__20220621_zWTptl2stU5a"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 21, 2022</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityRegistrantName_c20220621__20220621_zHEeQCU0DHsf"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" name="dei:EntityRegistrantName">ABVC
BIOPHARMA, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20220621__20220621_zR6njMzwljU"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_909_edei--EntityFileNumber_c20220621__20220621_zps5v2jG3xD2"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" name="dei:EntityFileNumber">333-91436</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityTaxIdentificationNumber_c20220621__20220621_zrbPjXevo7b3"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" name="dei:EntityTaxIdentificationNumber">26-0014658</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction<br />
    of incorporation)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer<br />
    Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_901_edei--EntityAddressAddressLine1_c20220621__20220621_zrVqUAf7vkU3"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" name="dei:EntityAddressAddressLine1">44370
    Old Warm Springs Blvd.</ix:nonNumeric></span></b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90B_edei--EntityAddressCityOrTown_c20220621__20220621_zttTbulkl8A2"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" name="dei:EntityAddressCityOrTown">Fremont</ix:nonNumeric></span>,
    <span id="xdx_905_edei--EntityAddressStateOrProvince_c20220621__20220621_zmiKVWHtoJK1"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" name="dei:EntityAddressStateOrProvince">CA</ix:nonNumeric> </span></b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_900_edei--EntityAddressPostalZipCode_c20220621__20220621_zkq185B8vLjh"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" name="dei:EntityAddressPostalZipCode">94538</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive
    offices)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registrant&#8217;s
telephone number including area code: <b>(<span id="xdx_908_edei--CityAreaCode_c20220621__20220621_z2ltffNKjTaa"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" name="dei:CityAreaCode">510</ix:nonNumeric></span>) <span id="xdx_905_edei--LocalPhoneNumber_c20220621__20220621_z3zx0lYBF47f"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" name="dei:LocalPhoneNumber">668-0881</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former
name or former address, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--WrittenCommunications_c20220621__20220621_zC5LNk7upURi"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications
    pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--SolicitingMaterial_c20220621__20220621_zosrVnJuNMYe"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the
    Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--PreCommencementTenderOffer_c20220621__20220621_zNHfyb9g28ki"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b)
    under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20220621__20220621_zf44otm4AQzg"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c)
    under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Each Class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--Security12bTitle_c20220621__20220621_zro4v7FJdEM3"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" name="dei:Security12bTitle">Common Stock, par value
    $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_903_edei--TradingSymbol_c20220621__20220621_z5bAp97Okzr4"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" name="dei:TradingSymbol">ABVC</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_906_edei--SecurityExchangeName_c20220621__20220621_zqiXYuvpW6D1"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market
    LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933
(&#167; 230.405 of this chapter) or Rule 12b&#8211;2 of the Securities Exchange Act of 1934 (&#167; 240.12b&#8211;2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company&#160;<span id="xdx_904_edei--EntityEmergingGrowthCompany_c20220621__20220621_zKo6QHDr3J65"><ix:nonNumeric contextRef="From2022-06-21to2022-06-21" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
8.01 Other Information</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 10, 2022, ABVC BioPharma, Inc. (the &#8220;Company&#8221;) expanded its co-development partnership with Rgene Corporation (&#8220;Rgene&#8221;).
<span style="background-color: white">BioKey, Inc., a California corporation and wholly-owned subsidiary of the Company (&#8220;BioKey&#8221;),
</span>entered into a Clinical Development Service Agreement with Rgene (&#8220;Service Agreement&#8221;) to guide certain Rgene drug
products, RGC-1501 for the treatment of Non-Small Cell Lung Cancer (NSCLC), RGC-1502 for the treatment of pancreatic cancer and RGC 1503
for the treatment of colorectal cancer patients, through completion of Phase II clinical studies under U.S. FDA IND regulatory requirements
(the &#8220;Rgene Studies&#8221;). Under the terms of the Service Agreement, BioKey is eligible to receive payments totaling up to $3.0
million over a 3-year period with each payment amount to be determined by certain regulatory milestones obtained during the agreement
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
a series of transactions over the past 5 years, the Company and Rgene have co-developed the three drug products covered by the Service
Agreement, which has resulted in the Company owning 31.62% of Rgene.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the Rgene Studies, the Company agreed to loan $1.0 million to Rgene, for which Rgene has provided the Company with a 5% working
capital convertible loan (the &#8220;Note&#8221;). If the Note is fully converted, the Company will own an additional 6.4% of Rgene.
Rgene will repay the Company in two equal installments in the second and third quarter of fiscal 2022. The Company may convert the Note
at any time into shares of Rgene&#8217;s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount
of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in
the Note. The Note includes standard events of default, as well as a cross default provision pursuant to which a breach of the Service
Agreement will trigger an event of default under the Note if not cured after 5 business days of written notice regarding the breach is
provided. Upon an event of default, the outstanding principal and any accrued and unpaid interest shall be immediately due and payable.
&#160;&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Rgene
has further agreed, effective July 1, 2022, to provide the Company with a seat on Rgene&#8217;s Board of Directors until the loan is
repaid in full. The Company has nominated Dr. Jiang, its Chief Strategy Officer and Director to occupy that seat; Dr. Jiang is also one
of the Company&#8217;s largest shareholders, owning 12.8% of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">BLEX
404, a new drug under clinical development covered by the Service Agreement, is extracted from Maitake mushroom (<i>Grifola frondosa),
</i>an edible mushroom. Its immunological effects and the safety have been demonstrated in two Phase I/II clinical studies performed
at Memorial Sloan Kettering Cancer Center (MSKCC) with breast cancer and myelodysplastic syndromes (MDS) patients.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Service Agreement shall remain in effect until the expiration date of the last patent and automatically renew for 5 more years unless
terminated earlier by either party with six months written notice. Either party may terminate the Service Agreement for cause by providing
30 days written notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
June 21, 2022, the Company issued a press release regarding the Rgene Studies. A copy of the press release is being filed as Exhibit
99.1 attached hereto and is incorporated by reference herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Rgene Studies is a&#160;<i>related</i>&#160;<i>party</i>&#160;transaction and will be conducted at arm&#8217;s length. In addition to
the Company&#8217;s board of directors approving the Rgene Studies, the Company&#8217;s audit committee and special committee also approved
it. The Board believes it is in the Company&#8217;s best interest for BioKey to proceed with the Rgene Studies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the Service Agreement and Note is attached hereto as Exhibit 10.1 and Exhibit 10.2, respectively and is incorporated by reference
herein.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
9.01 Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<i>Exhibits. </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit
    <br />
    Number</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ea161846ex10-1_abvcbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical Development Service Agreement with Rgene (portions of the exhibit have been omitted because they (i) are not material and (ii) is the type of information that the registrant treats as private or confidential.)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="ea161846ex10-2_abvcbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promissory Note dated June 16, 2022</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1 </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="ea161846ex99-1_abvcbio.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated June 21, 2022</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the
    Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">&#160;</div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ABVC BioPharma, Inc.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 4%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June 21, 2022</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Howard
    Doong</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Howard Doong</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>












</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwjAQhU/QOwxZiyZBXXSnRUWsIkXEbbBTCbaZMol/R/KWxhZxGBiG9773hBiIFS1tjQyneZHDAZu2NgGhwAoZ3RmjI1tvUoi3wIv1gY0L3fsDM4oMRmYyVGMThc56tx7LFOR0pNVIa1AynUiYbUXy1TNylS3RBWtqMK6EPVPLFoPhV59wME9y1Ly6qiOyt+RSUEPZy2/QUmnY0d08iK8e8jwTyaCbRKyYbu235uYDNbCosYldvkf/m3wADJxJNQ== -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ea161846ex10-1_abvcbio.htm
<DESCRIPTION>CLINICAL DEVELOPMENT SERVICE AGREEMENT WITH RGENE (PORTIONS OF THE EXHIBIT HAVE BEEN OMITTED BECAUSE THEY (I) ARE NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.)
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>**CERTAIN INFORMATION, MARKED BY [***], HAS
BEEN EXCLUDED BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.**</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Clinical
Development Service Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><FONT STYLE="font-variant: small-caps"><B>This Clinical Development
Service Agreement</B></FONT><B> </B>(&ldquo;<B>Agreement</B>&rdquo;) shall be signed by the following parties on or before June 10, 2022:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in">RGENE Corporation. (&ldquo;<FONT STYLE="font-size: 10pt"><B>RGENE</B></FONT>&rdquo;),
a company organized and existing under the Laws of Taiwan, Republic of China, with its registered office at 5F, No. 148, Songjiang Rd.,
Zhongshan Dist., Taipei City 104492, Taiwan (R.O.C.) and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><B>BioKey, Inc. </B>(&ldquo;<B>BioKey</B>&rdquo;)<B>, </B>a
company incorporated under the Laws of California and having its principal place of business at 44370 Old Warm Springs Blvd., Fremont,
CA 94538, USA</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in"><FONT STYLE="font-size: 10pt">RGENE </FONT>and BioKey shall
be referred to individually as a &ldquo;<B>Party</B>&rdquo; and collectively as the &ldquo;<B>Parties</B>&rdquo;.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><U>Whereas</U> <FONT STYLE="font-size: 10pt">RGENE</FONT></B>
has been established its own technology and owned exclusive licensing rights to use the proprietary technologies and confidential information
for the following products (&ldquo;Product&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -12pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 12pt">1.</TD><TD>RGC-1501: NSCLC</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -12pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 12pt">2.</TD><TD>RGC-1502: Pancreatic Cancer</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -12pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24pt"></TD><TD STYLE="width: 12pt">3.</TD><TD>RGC-1503: Colorectal Cancer</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><U>Whereas</U></B> BioKey is a CDMO
service provider for nutritional and pharmaceutical products, as well as medical devices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><U>Whereas</U></B> BioKey is willing
to provide clinical development service of Product in the Field (as defined hereafter) to RGENE;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><B><U>Whereas</U></B> RGENE agrees to
use BioKey&rsquo;s experience and capability and enters into the Agreement. Herein, it is agreed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 1. Definitions and Interpretation</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 1.45pt">1.1
&ldquo;Confidential Information&rdquo; shall mean all confidential, proprietary, trade secret, or non-public information, data and
experience, whether of scientific, technical, engineering, operational or economic nature, disclosed by one of the <B>Parties </B>(the
&ldquo;Disclosing Party&rdquo;) to the other <B>Party </B>(the &ldquo;Recipient&rdquo;) for this Clinical Development Service
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 1.1pt"><FONT STYLE="font-size: 10pt">1.2
&ldquo;Confidential Materials&rdquo; shall mean any document, diskette, tape, writing or other tangible item to the extent that such
item contains or embodies any Confidential Information, whether in </FONT>printed, handwritten, electronic, coded, magnetic or other
form and whether delivered by a Disclosing <B>Party </B>or made by a Recipient.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 1.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 1.1pt"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 46%; padding-top: 1pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">CONFIDENTIAL</FONT></TD><TD STYLE="text-align: center; width: 9%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 45%; padding-top: 1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">RGENE </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">/BioKey</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 1.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.7pt">1.3
&ldquo;Data&rdquo; shall mean all research data, technical data, test and development data, CMC (chemistry, manufacturing and
control), pre-clinical and clinical data, formulations, processes, ideas, protocols, regulatory files and the like which are
developed by either <B>Party</B> under the Development Program in connection with its performance of this Clinical Development
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 1.1pt">1.4
&ldquo;Field&rdquo; shall mean drug and therapeutic use of the Product based upon the Health Registration Approval and in no event
include the use of the Product for functional food, health food nor health supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 1.45pt">1.5
&ldquo;Intellectual Property&rdquo; shall mean any patent, copyright, mask work, trade secret, trademark or other proprietary right;
including, without limitation, all domestic and foreign applications and registrations therefore, and all renewals and extensions
relating thereto; with respect to patent application and patents, all domestic and foreign divisional, continuations,
continuations-in-part, substitutions, reissues, re-examinations, renewals and extensions relating thereto; all goodwill associated
therewith, and all benefits, privileges, causes of action and remedies relating to any of the foregoing proprietary rights
(including, without limitation, the right to use for all past, current or future infringements or violations of the foregoing
proprietary rights, and the right to settle and retain proceeds from any such actions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 1.6 &ldquo;CTA&rdquo; means clinical trial application to be required before execution of any clinical trial;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">1.7 &ldquo;Approval&rdquo;
means any and all approvals, permits, operating licenses, ratifications, registrations, consents, record-filings or other form of permission
issued by any regulatory or government body in US<FONT STYLE="font-family: Times New Roman, Times, Serif">&#65292;</FONT>Taiwan or PRC
in the exercise of its functions under the applicable law, and &ldquo;Approve&rdquo; shall be construed accordingly;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">1.8 &ldquo;Clinical
Development Service&rdquo; means all the strategic planning, project management and coordination provided by ABVC for the said service.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">1.9 &ldquo;Pass-through
Cost&rdquo; means all the incurred cost during the execution of clinical studies including the clinical drug supplies and drug formulation
development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <B>2.</B> <B>Agreement to</B> BioKey</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.35pt">2.1&nbsp;<B>RGENE
</B>agrees to use BioKey&rsquo;s experience and capability and enters into the Clinical Development Service Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.35pt">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 46%; padding-top: 1pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">CONFIDENTIAL</FONT></TD><TD STYLE="text-align: center; width: 9%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 45%; padding-top: 1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">RGENE </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">/BioKey</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.35pt">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 3. Payment</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3.1 Total service payment to BioKey for BioKey&rsquo;s
Clinical Development Service is three million U .S. dollars (USD3,000,000).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0in">3.2&nbsp;Per the good relationship
in between both Parties, the payment shall be in installments as follow:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt">3.2.1&nbsp;First payment:
[***]% in cash of total contract amount shall be paid no later than [***] ([***]) days after the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 27pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt">3.2.2&nbsp;After making
first payment, <B>RGENE </B>will deliver all Data to BioKey within [***] ([***]) days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify">3.2.3&nbsp;The
rest [***]% of total amount: <B>RGENE </B>should pay according to the Service milestones described in Exhibit A. BioKey will issue an
invoice for the applicable amount payable for each milestone and present the deliverables evidencing the completion of such milestone.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0in">3.3&nbsp;If any payment
made under this Agreement shall be subject to withholding tax under the applicable law, each payment will be less any such applicable
withholding tax.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6pt">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 4. Development responsibilities</P>



<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0in">4.1&nbsp;BioKey will utilize
its global clinical development capability and be responsible to develop Product to the completions of Phase II clinical studies under
US IND.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0in">4.2&nbsp;RGENE will pay
BioKey the service fee according to the deliverables described in 3.2.3 (see Exhibit A).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 5. Confidentiality</P>



<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The Parties agree that during the term
of this Service Agreement and thereafter [***] Confidential Information exchanged during this Service Agreement and will be accorded confidential
treatment and shall not be used for any other purpose than the performance of this Service Agreement and the exercise of the rights herein
provided.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">The Recipient&rsquo;s obligation hereunder
shall not apply to:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 0in; text-indent: 0.35pt">(a)&nbsp;Information
which is now or hereafter becomes part of the public domain in other ways than by faults, acts or omissions of the Recipient;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">(b) Information which
the Recipient can show by sufficient evidence was in its own possession prior to the time of receipt from the Disclosing Party or is
independently developed by or for the Recipient without reliance upon or use of any of the Disclosing Party&rsquo;s Confidential
Information or Confidential Materials;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 46%; padding-top: 1pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">CONFIDENTIAL</FONT></TD><TD STYLE="text-align: center; width: 9%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 45%; padding-top: 1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">RGENE </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">/BioKey</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0.35pt">(c)&nbsp;Information
which is required to be disclosed by statute or governmental rule or regulation or by a court or administrative body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 1.1pt">Nothing herein shall
prevent RGENE or BioKey from disclosing any of such Confidential Information to the extent that (i) such Confidential Information is disclosed
in connection with the securing of the IND or NDA, (ii) such information is disclosed for the purpose of obtaining a governmental approval
for the manufacture and/or sale of or effectuating the development, marketing and promotion of any Product and/or API or (iii) such information
is disclosed to the Sub-licensee(s) of <FONT STYLE="font-size: 10pt"><B>RGENE </B></FONT>or BioKey for the use thereof upon executing
a separate confidentiality disclosure agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 6. Duration and Termination</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 6.1 Duration</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">This Collaborative Agreement shall, once
signed by both Parties, remain in effect until the expiration date of the last patent and automatically renew for [***] unless either
Party gives the other Party [***] written notice of termination prior to the expiration date of the term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 6.2 Termination for Cause</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.35pt">This Collaborative
Agreement can be terminated by either <B>Party </B>for any of the following causes by giving to the other <B>Party </B>(&ldquo;Breaching
Party&rdquo;) [***] written notice of its intention to terminate for such causes as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.35pt"></TD><TD STYLE="width: 21pt">(a)</TD><TD STYLE="text-align: justify">If Breaching Party materially breaches any provision of this Agreement and such breach is not cured within
[***] following the written notice by Non-breaching Party; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 24.35pt"></TD><TD STYLE="width: 21pt">(b)</TD><TD STYLE="text-align: justify">If a Party is the subject of a voluntary petition in bankruptcy or any voluntary proceeding relating to
insolvency, receivership, liquidation, or composition for the benefit of creditors, if such petition or proceeding is not dismissed within
[***] of filing, or becomes the subject of any involuntary petition in bankruptcy or any involuntary proceeding relating to insolvency,
receivership, liquidation, or composition for the benefit of creditors, if such petition or proceeding is not dismissed within [***] of
filling.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">Termination is not
the sole or exclusive remedy under this Agreement and, whether or not termination is affected; all other rights and remedies at law or
equity will remain available.</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 46%; padding-top: 1pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">CONFIDENTIAL</FONT></TD><TD STYLE="text-align: center; width: 9%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 45%; padding-top: 1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">RGENE </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">/BioKey</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.35pt">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 7. Miscellaneous</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 7.1 Notice</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: -0.35pt">All notices, requests,
demands and other communications to be given in accordance with this Agreement shall be given in writing and/or by prepaid registered
mail or receipt return requested to the other Party at the following addresses:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-indent: 0in"><U>If to RGENE Corporation:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt">RGENE Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt">5F, No. 148, Songjiang Rd., Zhongshan Dist., Taipei City 104492,
Taiwan (R.O.C.)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt">Attention: Syi Su, Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt">Title: CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 42pt; text-indent: 0in"><U>If to BioKey:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt">BioKey, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt">44370 Old Warm Springs Blvd., Fremont, CA 94538</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt">Attention:
Chi-Hsin Richard King, Ph.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 60pt">Title: CSO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 7.2 Applicable Law</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">This Agreement and any disputes arising
out of or relating thereto, including, without limitation, its interpretation, construction, performance, and enforcement shall be governed
by and construed in accordance with the laws of Taiwan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> 7.3 Dispute Dissolution</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0.35pt">Both Parties shall
endeavor to settle amicably and promptly any disputes, controversies and differences which may arise between the Parties out of or in
relation to this Agreement or any breach thereof. In case such an amicable settlement is not attained, the matter shall be finally settled
by arbitration according to the Rules of Conciliation and Arbitration of the International Chamber of Commerce, which rules shall be deemed
incorporated into this paragraph. The place of arbitration will be Taipei (Taiwan).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0in"><FONT STYLE="font-weight: normal">7.4
Addendum or amendment may be added upon mutual agreement of the parties</FONT>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 46%; padding-top: 1pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">CONFIDENTIAL</FONT></TD><TD STYLE="text-align: center; width: 9%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 45%; padding-top: 1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">RGENE </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">/BioKey</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0in">IN WITNESS WHEREOF <FONT STYLE="font-weight: normal">the</FONT>
Parties <FONT STYLE="font-weight: normal">hereto have caused this Collaborative Agreement to be executed, in duplicate, each </FONT>Party
<FONT STYLE="font-weight: normal">taking a copy, as of the Effective Date.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0in">RGENE Corporation</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 5%; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">By:</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 35%; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    <FONT STYLE="font-weight: normal">Syi Su, Ph.D.</FONT></FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 60%; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Name:</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Syi
    Su, Ph.D.</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">Title:</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">CEO</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">Date:</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">June
    8, 2022</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 0in">BioKey, Inc.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; font-weight: bold; text-indent: 0in"><FONT STYLE="font-weight: normal">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%; font-weight: bold; text-indent: 0in"><FONT STYLE="font-weight: normal">/s/ TS Jiang</FONT></TD>
    <TD STYLE="width: 60%; font-weight: bold; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-indent: 0in"><FONT STYLE="font-weight: normal">Name:</FONT>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-indent: 0in"><FONT STYLE="font-weight: normal">TS Jiang, Ph.
    D., EMBA</FONT></TD>
    <TD STYLE="font-weight: bold; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-indent: 0in"><FONT STYLE="font-weight: normal">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-indent: 0in"><FONT STYLE="font-weight: normal">CEO</FONT></TD>
    <TD STYLE="font-weight: bold; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-indent: 0in">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-indent: 0in">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; text-indent: 0in"><FONT STYLE="font-weight: normal">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-indent: 0in"><FONT STYLE="font-weight: normal">6/10/2022</FONT></TD>
    <TD STYLE="font-weight: bold; text-indent: 0in">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 46%; padding-top: 1pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">CONFIDENTIAL</FONT></TD><TD STYLE="text-align: center; width: 9%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 45%; padding-top: 1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">RGENE </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">/BioKey</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Exhibit A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Milestone payments based
upon the development stages of Product</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 65%; border: black 1pt solid; padding-top: 0.05pt; padding-left: 29.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Within [***] days after the Effective Date</B></FONT></TD>
    <TD STYLE="text-align: center; width: 35%; border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 0.05pt; padding-left: 5.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">[***]% of Total Payment</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 0.05pt; padding-left: 5.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">(1) An additional US FDA/TFDA IND approval</FONT></TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 0.05pt; padding-left: 5.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">[***]% of Total Payment</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.25pt">(2) The first Phase IIA under US FDA/TFDA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.25pt">completion</P></TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 7.95pt; padding-left: 5.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">[***]% of Total Payment</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.25pt">(3) The first Phase IIB under US FDA/TFDA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.25pt">completion</P></TD>
    <TD STYLE="text-align: center; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 8.2pt; padding-left: 5.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">[***]% of Total Payment</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-top: 0.05pt; padding-right: 104.1pt; padding-left: 122.25pt; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>TOTAL</B></FONT></TD>
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; padding-top: 0.05pt; padding-right: 57.65pt; padding-left: 58.1pt; text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>100%</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="width: 46%; padding-top: 1pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">CONFIDENTIAL</FONT></TD><TD STYLE="text-align: center; width: 9%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 45%; padding-top: 1pt; font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">RGENE </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">/BioKey</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ea161846ex10-2_abvcbio.htm
<DESCRIPTION>PROMISSORY NOTE DATED JUNE 16, 2022
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RGENE
Corporation&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Promissory
Note</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Principal
    Amount: $1,000,000 U.S. Dollars&nbsp;&nbsp;</B>&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; width: 50%">Issuance Date:&nbsp; June
    16, 2022</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
VALUE RECEIVED,</B>&nbsp; RGENE Corporation, a Taiwan corporation (the &ldquo;<B>Company</B>&rdquo;), hereby promises to pay to the order
of ABVC BioPharma, Inc. or its registered assigns (&ldquo;<B>Holder</B>&rdquo;) the amount set out above as the Principal Amount (the
&ldquo;<B>Principal</B>&rdquo;) when due, whether upon the Maturity Date (as defined below) or earlier in accordance with the terms hereof,
and to pay interest (&ldquo;<B>Interest</B>&rdquo;) on any outstanding Principal at the applicable Interest Rate (as defined below) from
the date set out above as the Issuance Date (the &ldquo;Issuance&nbsp;Date&rdquo;) until the same becomes due and payable, whether upon
the Maturity Date, acceleration or otherwise (in each case in accordance with the terms hereof). The amount set out above will be delivered
from the Holder to the Company by 2 installments, $500,000 in Q2-2022 and remaining $500,000 in Q3-2022. This Promissory Note, including
all Promissory Notes issued in exchange, transfer or replacement hereof, is referred to as this &ldquo;<B>Note</B>&rdquo;. Certain capitalized
terms used herein are defined in Section 19.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.&nbsp;<U>PAYMENTS
OF PRINCIPAL</U>. Subject to the conversion of the Note as described in Section 5, the Company shall pay to the Holder an amount in cash
representing all outstanding Principal and accrued and unpaid Interest on June 15, 2023, the twelve (12) month anniversary of the Issuance
Date (the &ldquo;<B>Maturity Date</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.&nbsp;<U>INTEREST
RATE</U>. Interest shall accrue on the unpaid principal balance of this Note at the rate of five percent (5%) per annum (the &ldquo;<B>Interest
Rate</B>&rdquo;). Interest shall be calculated from and include the Issuance Date and shall be calculated on an actual/360-day basis
and shall be payable on the Maturity Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.&nbsp;<U>RIGHTS
UPON EVENT OF DEFAULT</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<U>Event of Default</U>. Each of the following events shall constitute an &ldquo;<B>Event of Default</B>&rdquo;:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;the
Company&rsquo;s failure to pay to the Holder any amount of Principal, Interest, or other amounts when and as due under this Note or any
other Transaction Document or any other agreement, document, certificate or other instrument delivered in connection with the transactions
contemplated hereby and thereby, except, in the case of a failure to pay Interest when and as due, in which case only if such failure
remains uncured for a period of at least five (5) days from the date when a written notice regarding the failure to pay Interest is given
by the Holder of the Note;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;bankruptcy,
insolvency, reorganization or liquidation proceedings or other proceedings for the relief of debtors shall be instituted by or against
by a third party, shall not be dismissed within thirty (30) days of their initiation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)&nbsp;the
commencement by the Company of a voluntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency,
reorganization or other similar law or of any other case or proceeding to be adjudicated as bankrupt or insolvent, or the consent by
it to the entry of a decree, order, judgment or other similar document in respect of the Company in an involuntary case or proceeding
under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or to the commencement of
any bankruptcy or insolvency case or proceeding against it, or the filing by it of a petition or answer or consent seeking reorganization
or relief under any applicable federal, state or foreign law, or the consent by it to the filing of such petition or to the appointment
of or taking possession by a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company
or of any substantial part of their properties, or the making by it of an assignment for the benefit of creditors, or the execution of
a composition of debts, or the occurrence of any other similar federal, state or foreign proceeding, or the admission by it in writing
of its inability to pay its debts generally as they become due, the taking of corporate action by the Company in furtherance of any such
action or the taking of any action by any Person to commence a UCC foreclosure sale or any other similar action under federal, state
or foreign law;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)&nbsp;the
entry by a court of (i) a decree, order, judgment or other similar document in respect of the Company of a voluntary or involuntary case
or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or (ii) a decree,
order, judgment or other similar document adjudging the as bankrupt or insolvent, or approving as properly filed a petition seeking liquidation,
reorganization, arrangement, adjustment or composition of or in respect of the Company under any applicable federal, state or foreign
law or (iii) a decree, order, judgment or other similar document appointing a custodian, receiver, liquidator, assignee, trustee, sequestrator
or other similar official of the Company or of any substantial part of their property, or ordering the winding up or liquidation of its
affairs, and the continuance of any such decree, order, judgment or other similar document or any such other decree, order, judgment
or other similar document unstayed and in effect for a period of thirty (30) consecutive days;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&nbsp;other
than as specifically set forth in another clause of this Section 3(a),&nbsp;the Company breaches any representation, warranty, covenant
or other term or condition of any Transaction Document, except, in the case of a breach of a covenant or other term or condition that
is curable, only if such breach remains uncured for a period of five (5) consecutive Business Days from the date when a written notice
of such breach is provided;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
<U>Notice of an Event of Default</U>. As soon as possible and in any event within seven (7) days after the Company becomes aware that
an Event of Default has occurred and has not been cured, the Company shall notify the Holder in writing of the nature, extent and time
of and the facts surrounding such Event of Default, and the action, if any, that the Company proposes to take with respect to such Event
of Default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
<U>Acceleration of Maturity Date</U>. Upon the occurrence of an Event of Default, the entire unpaid and outstanding Principal plus any
accrued and unpaid Interest shall be immediately due and payable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.&nbsp;<U>NONCIRCUMVENTION</U>.
The Company hereby covenants and agrees that the Company will not, by amendment of its Certificate of Incorporation, or through any reorganization,
transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action,
avoid or seek to avoid the observance or performance of any of the terms of this Note, and will at all times in good faith carry out
all of the provisions of this Note and take all action as may be required to protect the rights of the Holder of this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.&nbsp;<U>PREPAYMENT;
CONVERSION</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;<U>Voluntary
Prepayment</U>. The Company may prepay the outstanding Principal and accrued but unpaid interest of this Note at any time, in whole or
in part, without penalty or prepayment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;<U>Conversion</U>.
At any time during the Conversion Period as defined below, the Holder may convert the unpaid and outstanding Principal into shares of
the Company&rsquo;s common stock at either (i) a fixed conversion price equal to US $1 per share of Common Stock (the &ldquo;Conversion
Price&rdquo;) or (ii) 20% discount of the stock price for the most recent offerings, whichever is lower. The Conversion Period shall
commence on the Issuance Date and end on the Maturity Date of this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c) <U>Mechanics
of Conversion</U>. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> i. <U>Conversion
Shares Issuable Upon Conversion</U>. The number of shares issuable upon a conversion (the &ldquo;<B>Conversion Shares</B>&rdquo;) pursuant
to Section 5(b) hereunder shall be determined by the quotient obtained by dividing the outstanding principal amount of this Note and
accrued but unpaid interest thereon to be converted by the Conversion Price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> ii. <U>Delivery
of Certificate Upon Conversion</U>. Not later than seven (7) Business Days after each conversion date (the &ldquo;<B>Share Delivery Date</B>&rdquo;),
the Company shall deliver, or cause to be delivered, to the Holder a certificate or certificates representing the Conversion Shares being
acquired upon the conversion of this Note, in whole or in part.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> iii.
<U>Fractional Shares</U>. No fractional shares or scrip representing fractional shares shall be issued upon the conversion of this Note.
As to any fraction of a share which the Holder would otherwise be entitled to receive upon such conversion, the Company shall at its
election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Conversion
Price or round up to the next whole share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;<U>Certain
Adjustments</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> i. <U>Stock
Dividends and Stock Splits</U>. If the Company, at any time while this Note is outstanding: (i) subdivides outstanding shares of common
stock into a larger number of shares, (ii) combines (including by way of a reverse stock split) outstanding shares of common stock into
a smaller number of shares or (iii) issues, in the event of a reclassification of shares of the common stock, any shares of capital stock
of the Company, then the Fixed Conversion Price shall be multiplied by a fraction of which the numerator shall be the number of shares
of common stock (excluding any treasury shares of the Company) outstanding immediately before such event, and of which the denominator
shall be the number of shares of common stock outstanding immediately after such event. Any adjustment made pursuant to this Section
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution
and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> ii. <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 5(d)(i) above, if at any time while the Note is outstanding
the Company grants, issues or sells any common stock equivalents or rights to purchase stock, warrants, securities or other property
pro rata to the record holders of any class of shares of common stock (the &ldquo;<B>Purchase Rights</B>&rdquo;), then the Holder will
be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have
acquired if the Holder had held the number of shares of common stock acquirable upon complete conversion of this Note (without regard
to any limitations on exercise hereof) immediately before the date on which a record is taken for the grant, issuance or sale of such
Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined
for the grant, issue or sale of such Purchase Rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> iii. <U>Pro
Rata Distributions</U>. During such time as this Note is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of common stock, by way of return of capital or otherwise (including,
without limitation, any distribution of cash, property or options by way of a dividend, spin off, reclassification, corporate rearrangement,
scheme of arrangement or other similar transaction) (a &ldquo;<B>Distribution</B>&rdquo;), at any time after the issuance of this Note,
then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have
participated therein if the Holder had held the number of shares of common stock acquirable upon complete exercise of this Note (without
regard to any limitations on exercise hereof) immediately before the date of which a record is taken for such Distribution, or, if no
such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in
such Distribution.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> iv. <U>Calculations</U>.
All calculations under this Section 5(d) shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For
purposes of this Section 5(d), the number of shares of common stock deemed to be issued and outstanding as of a given date shall be the
sum of the number of shares of common stock (excluding any treasury shares of Borrower) issued and outstanding.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 31.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"> v.
 <U>Notice of Adjustment to Conversion Price</U>. Whenever the Conversion Price is adjusted pursuant to any provision of this Section,
the Company shall promptly deliver to each Holder a notice setting forth the Fixed Conversion Price with three (3) Business Days after
such adjustment and setting forth a brief statement of the facts requiring such adjustment. Failure to provide such notice shall constitute
an Event of Default, subject to be a three (3) Business Days&rsquo; curing period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.&nbsp;<U>COVENANTS</U>.
Until so long as no Principal or accrued but unpaid interest remains outstanding:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;<U>Preservation
of Existence.</U>&nbsp;The Company shall maintain and preserve its existence, rights and privileges, and become or remain duly qualified
and in good standing in each jurisdiction in which the character of the properties owned or leased by it or in which the transaction
of its business makes such qualification necessary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;<U>Use
of Proceeds. </U>The proceeds from this Note will be used for research and development expenses, as well as the working capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.&nbsp;Conversion
Limitation. The Company shall not effect any conversion of this Note, and a Holder shall not have the right to convert any portion of
this Note, to the extent that after giving effect to the conversion set forth on the applicable Notice of Conversion, the Holder (together
with the Holder's Affiliates, and any Persons acting as a group together with the Holder or any of the Holder's Affiliates) would beneficially
own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp; For purposes of the foregoing sentence, the number of
shares of Common Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable
upon conversion of this Note with respect to which such determination is being made, but shall exclude the number of shares of Common
Stock which are issuable upon (i) conversion of the remaining, unconverted principal amount of this Note beneficially owned by the Holder
or any of its Affiliates and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of the Company
subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any
of its Affiliates.&nbsp; Except as set forth in the preceding sentence, for purposes of this Section, beneficial ownership shall be calculated
in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder.&nbsp; To the extent that the
limitation contained in this Section applies, the determination of whether this Note is convertible (in relation to other securities
owned by the Holder together with any Affiliates) and of which principal amount of this Note is convertible shall be in the sole discretion
of the Holder, and the submission of a Notice of Conversion shall be deemed to be the Holder's determination of whether this Note may
be converted (in relation to other securities owned by the Holder together with any Affiliates) and which principal amount of this Note
is convertible, in each case subject to the Beneficial Ownership Limitation. To ensure compliance with this restriction, the Holder will
be deemed to represent to the Company each time it delivers a Notice of Conversion that such Notice of Conversion has not violated the
restrictions set forth in this paragraph and the Company shall have no obligation to verify or confirm the accuracy of such determination.&nbsp;In
addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange
Act and the rules and regulations promulgated thereunder. For purposes of this Section, in determining the number of outstanding shares
of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as stated in the most recent of the following:
(i) the Company's most recent periodic or annual report filed with the Commission, as the case may be, (ii) a more recent public announcement
by the Company, or (iii) a more recent written notice by the Company or the Company's transfer agent setting forth the number of shares
of Common Stock outstanding.&nbsp; Upon the written or oral request of a Holder, the Company shall within two Trading Days confirm orally
and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp; In any case, the number of outstanding shares
of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Note,
by the Holder or its Affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;Beneficial
Ownership Limitation&rdquo; shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to
the issuance of shares of Common Stock issuable upon conversion of this Note held by the Holder.&nbsp; The Holder, upon not less than
61 days' prior notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section, provided
that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately
after giving effect to the issuance of shares of Common Stock upon conversion of this Note held by the Holder and the Beneficial Ownership
Limitation provisions of this Section shall continue to apply.&nbsp; Any such increase or decrease will not be effective until the 61st&nbsp;day
after such notice is delivered to the Company. &nbsp;The Beneficial Ownership Limitation provisions of this paragraph shall be construed
and implemented in a manner otherwise than in strict conformity with the terms of this Section to correct this paragraph (or any portion
hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation contained herein or to make changes
or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply
to a successor holder of this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.&nbsp;<U>AMENDING
THE TERMS OF THIS NOTE</U>. The prior written consent of the Holder shall be required for any change or amendment to this Note.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.&nbsp;<U>TRANSFER</U>.
This Note may be offered, sold, assigned or transferred by the Holder with the written consent of the Company, which such consent shall
not be unreasonably withheld.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.&nbsp;<U>REISSUANCE
OF THIS NOTE</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;<U>Transfer</U>.
If this Note is to be transferred, the Holder shall surrender this Note to the Company, whereupon the Company will forthwith issue and
deliver upon the order of the Holder a new Note (in accordance with Section 10(d)), registered as the Holder may request, representing
the outstanding Principal being transferred by the Holder and, if less than the entire outstanding Principal is being transferred, a
new Note (in accordance with Section 10(d)) to the Holder representing the outstanding Principal not being transferred. The Holder and
any assignee, by acceptance of this Note, acknowledge and agree that, by reason of prepayment of any portion of this Note, the outstanding
Principal represented by this Note may be less than the Principal stated on the face of this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;<U>Lost,
Stolen or Mutilated Note</U>. Upon receipt by the Company of evidence reasonably satisfactory to the Company of the loss, theft, destruction
or mutilation of this Note (as to which a written certification and the indemnification contemplated below shall suffice as such evidence),
and, in the case of loss, theft or destruction, of any indemnification undertaking by the Holder to the Company in customary and reasonable
form and, in the case of mutilation, upon surrender and cancellation of this Note, the Company shall execute and deliver to the Holder
a new Note (in accordance with Section 10(d)) representing the outstanding Principal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;Note
Exchangeable for Different Denominations. This Note is exchangeable, upon the surrender hereof by the Holder at the principal office
of the Company, for a new Note or Notes (in accordance with Section 10(d) and in principal amounts of at least $1,000) representing in
the aggregate the outstanding Principal of this Note, and each such new Note will represent such portion of such outstanding Principal
as is designated by the Holder at the time of such surrender.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;<U>Issuance
of New Notes</U>. Whenever the Company is required to issue a new Note pursuant to the terms of this Note, such new Note (i) shall be
of like tenor with this Note, (ii) shall represent, as indicated on the face of such new Note, the Principal remaining outstanding (or
in the case of a new Note being issued pursuant to Section 10(a) or Section 10(c), the Principal designated by the Holder which, when
added to the principal represented by the other new Notes issued in connection with such issuance, does not exceed the Principal remaining
outstanding under this Note immediately prior to such issuance of new Notes), (iii) shall have an issuance date, as indicated on the
face of such new Note, which is the same as the Issuance Date of this Note, (iv) shall have the same rights and conditions as this Note,
and (v) shall represent accrued and unpaid Interest, from the Issuance Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.&nbsp;<U>REMEDIES,
CHARACTERIZATIONS, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF</U>. The remedies provided in this Note shall be cumulative and
in addition to all other remedies available under this Note and any of the other Transaction Documents at law or in equity (including
a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the Holder&rsquo;s right to pursue actual
and consequential damages for any failure by the Company to comply with the terms of this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.&nbsp;<U>CONSTRUCTION;
HEADINGS</U>. This Note shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed against any Person
as the drafter hereof. The headings of this Note are for convenience of reference and shall not form part of, or affect the interpretation
of, this Note. Terms used in this Note but defined in the other Transaction Documents shall have the meanings ascribed to such terms
on the Closing Date in such other Transaction Documents unless otherwise consented to in writing by the Holder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.&nbsp;<U>FAILURE
OR INDULGENCE NOT WAIVER</U>. No failure or delay on the part of the Holder in the exercise of any power, right or privilege hereunder
shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further
exercise thereof or of any other right, power or privilege. No waiver shall be effective unless it is in writing and signed by an authorized
representative of the waiving party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.&nbsp;<U>NOTICES;
CURRENCY; PAYMENTS</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;<U>Notices</U>.
Any notice or other communication required or permitted to be given hereunder shall be in writing sent by mail, facsimile with printed
confirmation, nationally recognized overnight carrier or personal delivery and shall be effective upon actual receipt of such notice,
to the following addresses until notice is received that any such address or contact information has been changed:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Company:  RGENE Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5F,
No. 148, Songjiang Rd., Zhongshan Dist., Taipei</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;City 104492, Taiwan (R.O.C.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
Holder:  &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ABVC BioPharma, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
44370 Old Warm Springs Blvd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">
Fremont, CA 94538 </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;<U>Currency</U>.
All dollar amounts referred to in this Note are in United States Dollars (&ldquo;<B>U.S. Dollars</B>&rdquo;), and all amounts owing under
this Note shall be paid in U.S. Dollars. All amounts denominated in other currencies (if any) shall be converted in the U.S. Dollar equivalent
amount in accordance with the Exchange Rate on the date of calculation (each, a &ldquo;<B>US Dollar Equivalent</B>&rdquo;). &ldquo;<B>Exchange
Rate</B>&rdquo;<B>&nbsp;</B>means, in relation to any amount of currency to be converted into U.S. Dollars pursuant to this Note, the
U.S. Dollar exchange rate as published in the Wall Street Journal on the relevant date of calculation (it being understood and agreed
that where an amount is calculated with reference to, or over, a period of time, the date of calculation shall be the final date of such
period of time).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;<U>Payments</U>.
Whenever any payment of cash is to be made by the Company to any Person pursuant to this Note, unless otherwise expressly set forth herein,
such payment shall be made in lawful money of the United States of America by a certified check drawn on the account of the Company and
sent via overnight courier service to such Person at such address as previously provided to the Company in writing (which address, in
the case of each of the Purchasers, shall initially be as set forth in the Securities Purchase Agreement), provided that the Holder may
elect to receive a payment of cash via wire transfer of immediately available funds by providing the Company with prior written notice
setting out such request and the Holder&rsquo;s wire transfer instructions. Whenever any amount expressed to be due by the terms of this
Note is due on any day which is not a Business Day, the same shall instead be due on the next succeeding day which is a Business Day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.&nbsp;<U>CANCELLATION</U>.
After all Principal, accrued Interest, and other amounts at any time owed on this Note have been paid in full or converted in full, this
Note shall automatically be deemed canceled, shall be surrendered to the Company for cancellation and shall not be reissued.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.&nbsp;<U>WAIVER
OF NOTICE</U>. To the extent permitted by law, the Company hereby irrevocably waives demand, notice, presentment, protest and all other
demands and notices in connection with the delivery, acceptance, performance, default or enforcement of this Note.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.&nbsp;<U>GOVERNING
LAW</U>. This Note shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to
its principles regarding conflicts of law. Each party agrees that all legal proceedings concerning the interpretation, enforcement and
defense of the transactions contemplated by any of the Transaction Documents (whether brought against a party hereto or its respective
Affiliates, directors, officers, shareholders, employees or agents) shall be commenced in the state and federal courts sitting in the
City of New York, Borough of Manhattan).&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.&nbsp;<U>MAXIMUM
PAYMENTS</U>. Nothing contained herein shall be deemed to establish or require the payment of a rate of interest or other charges in
excess of the maximum permitted by applicable law. In the event that the rate of interest required to be paid or other charges hereunder
exceed the maximum permitted by such law, any payments in excess of such maximum shall be credited against amounts owed by the Company
to the Holder and thus refunded to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">19.&nbsp;<U>CERTAIN
DEFINITIONS</U>. For purposes of this Note, the following terms shall have the following meanings:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;<B>&ldquo;Affiliate&rdquo;
</B>means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common
control with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;
&ldquo;<B>Business Day</B>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New
York are authorized or required by law to remain closed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Maturity&nbsp;Date&rdquo;
                                            shall mean the twelve (12) months anniversary after the Issuance Date.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Person</B>&rdquo;
                                            means &ldquo;person&rdquo; as such term is used for purposes of Section 13(d) or 14(d) of
                                            the Securities Exchange Act of 1934, as amended, including any individual, corporation, limited
                                            liability company, partnership, trust, unincorporated organization, government or any agency
                                            or political subdivision thereof, or any other entity or any group of persons.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Securities
                                            Act</B>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations
                                            promulgated thereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Transaction
                                            Documents&rdquo; means, collectively, the Notes, the Securities Purchase Agreement and any
                                            other agreements and instruments entered into or delivered by any of the parties hereto in
                                            connection with the transactions contemplated hereby and thereby, as may be amended from
                                            time to time.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[signature
page follows]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the Company has caused this Note to be duly executed as of the Issuance Date set out above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RGENE Corporation.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 33%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">/s/ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Syi Su, Ph.D.</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Syi Su, Ph.D.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>ea161846ex99-1_abvcbio.htm
<DESCRIPTION>PRESS RELEASE DATED JUNE 21, 2022
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ABVC BioPharma Expands Co-Development Partnership
with Rgene Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Fremont, CA (June 21, 2022) &ndash;
ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology,
CNS, and ophthalmology, today announced that it has expanded its co-development partnership with Rgene Corporation. BioKey, ABVC&rsquo;s
wholly owned subsidiary based in Fremont, California, has entered into a Clinical Development Service Agreement with Rgene to guide three
Rgene drug products, RGC-1501 for the treatment of Non-Small Cell Lung Cancer (NSCLC), RGC-1502 for the treatment of pancreatic cancer
and RGC 1503 for the treatment of colorectal cancer patients, through completion of Phase II clinical studies under U.S. FDA IND regulatory
requirements. Under the terms of the new Services Agreement, BioKey is eligible to receive payments totaling $3.0 million over a 3-year
period with each payment amount to be determined by certain regulatory milestones obtained during the agreement period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Through a series of transactions
over the past 5 years, ABVC and Rgene have co-developed the three drug products covered by the new Services Agreement resulting in ABVC
owning 31.62% of Rgene. In a separate agreement, ABVC, will provide a one year, $1.0 million, working capital convertible loan to Rgene
that, if fully converted, would result in ABVC owning an additional 6.4% of Rgene.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>
Rgene has further agreed, effective July 1, 2022, to provide a seat on the Rgene Board of Directors for Dr. TS Jiang until the loan is
repaid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">BLEX 404, the new drug under clinical
development covered by the service agreement, is extracted from Maitake mushroom (<I>Grifola frondosa), </I>an edible mushroom. Its immunological
effects and the safety have been demonstrated in two Phase I/II clinical studies performed at Memorial Sloan Kettering Cancer Center (MSKCC)
with breast cancer and myelodysplastic syndromes (MDS) patients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><FONT STYLE="font-weight: normal">&ldquo;We
are pleased to enter into this clinical development service contract with Rgene to advance three new oncology programs with our BLEX 404
drug&rdquo;, said Dr. Howard Doong, Chief Executive Officer of the Company; &ldquo;In addition, this contract will greatly enhance BioKey
financial profitability going forward.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>About ABVC BioPharma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">ABVC BioPharma is a clinical-stage
biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus<SUP>&reg;</SUP>) under development.
For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the
clinical development process at world-famous research institutions (such as Stanford University, University of California at San Francisco,
and Cedars-Sinai Medical Center). For Vitargus<SUP>&reg;</SUP>, the company intends to conduct the clinical trials through Phase III
at various locations throughout the globe.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">This press release contains &ldquo;forward-looking
statements.&rdquo; Such statements may be preceded by the words &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;plans,&rdquo;
&ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;projects,&rdquo; &ldquo;predicts,&rdquo; &ldquo;estimates,&rdquo; &ldquo;aims,&rdquo;
&ldquo;believes,&rdquo; &ldquo;hopes,&rdquo; &ldquo;potential,&rdquo; or similar words. Forward-looking statements are not guarantees
of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of
which are beyond the Company&rsquo;s control, and cannot be predicted or quantified, and, consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration
with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of
our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed
to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk
factors that may affect the realization of forward-looking statements is set forth in the Company&rsquo;s filings with the Securities
and Exchange Commission (SEC), including the Company&rsquo;s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors
are urged to read these documents free of charge on the SEC&rsquo;s website at&nbsp;<B>http://www.sec.gov</B>. The Company assumes no
obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ICR, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lucy Peng</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: +1 646-677-1872</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email:&nbsp;Lucy.Peng@icrinc.com</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>abvc-20220621.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 8qI5s7xRiXgen8uOYHxcWaiCacP9zp5yCZlBvGdzHak6/yksfGElvSjg8SGmIRwF -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:ABVC="http://abvcpharma.com/20220621" elementFormDefault="qualified" targetNamespace="http://abvcpharma.com/20220621">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://abvcpharma.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="abvc-20220621_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="abvc-20220621_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
    <import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
    <import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" />
    <import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
    <import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>abvc-20220621_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>abvc-20220621_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.14a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://abvcpharma.com/role/Cover" xlink:href="abvc-20220621.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://abvcpharma.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm139924342586224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 21, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 21,  2022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">333-91436<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ABVC
BIOPHARMA, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001173313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0014658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">44370
    Old Warm Springs Blvd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Fremont<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">668-0881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value
    $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ABVC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>ea161846-8k_abvcbio_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="abvc-20220621.xsd" xlink:type="simple"/>
    <context id="From2022-06-21to2022-06-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001173313</identifier>
        </entity>
        <period>
            <startDate>2022-06-21</startDate>
            <endDate>2022-06-21</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-06-21to2022-06-21">0001173313</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-06-21to2022-06-21">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2022-06-21to2022-06-21">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2022-06-21to2022-06-21">2022-06-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2022-06-21to2022-06-21">ABVC BIOPHARMA, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-06-21to2022-06-21">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2022-06-21to2022-06-21">333-91436</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-06-21to2022-06-21">26-0014658</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-06-21to2022-06-21">44370     Old Warm Springs Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2022-06-21to2022-06-21">Fremont</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-06-21to2022-06-21">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-06-21to2022-06-21">94538</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-06-21to2022-06-21">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-06-21to2022-06-21">668-0881</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2022-06-21to2022-06-21">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2022-06-21to2022-06-21">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2022-06-21to2022-06-21">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2022-06-21to2022-06-21">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2022-06-21to2022-06-21">Common Stock, par value     $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2022-06-21to2022-06-21">ABVC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2022-06-21to2022-06-21">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-06-21to2022-06-21">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MY?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^
MQ1' L#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\
M3;,,J^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4
MKS4@\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2
MG0P^\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 10
M2P,$%     @ [G#55)>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#
M, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%G;^OVJ5QD L9>3T\$MP>:4#M
M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y +AEFM[UD
M%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3
MY?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^
M-8+)#^Q^ %!+ P04    " #N<-54JL0B%C,!   B @  #P   'AL+W=O<FMB
M;V]K+GAM;(U1T6[", S\E2H?L!:T(0U17D#;D*8-C8GWT+K4(HDKQX6-KY_;
MJAK27O:4W-FZW%T6%^+3@>B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q
M8;!EK '$NW2:9;/46PQFN1BUMIS> A(H!"DHV1%[A$O\G7<P.6/$ SJ4[]ST
M=P<F\1C0XQ7*W&0FB35=7HCQ2D&LVQ5,SN5F,@SVP(+%'WK7F?RTA]@S8@\?
M5HWD9I:I8(4<I=_H]:UZ/(,N#Z@5>D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#B
MG/]3(U45%K"FHO409.B1P74&0ZRQB28)UD-N5G0&[O+H YMRR"9JZJ8IGJ,.
M>%,.]D9/)508H'Q3F:B\]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48<?R>Y0]0
M2P,$%     @ [G#55"0>FZ*M    ^ $  !H   !X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50J4,%3%U8*RX0!?,C$A+%K@JW+X4!
MD#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&
MO-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S"
M:+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X
M=/X!4$L#!!0    ( .YPU51ED'F2&0$  ,\#   3    6T-O;G1E;G1?5'EP
M97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*
MH!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJU
MDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7
MQ<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!Z
MVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$
M?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D<WC_0QI-^2!8ECFS_A[QA?_&\[Q
M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ [G#55 =!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" #N<-54*2JO/.X    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " #N<-54F5R<(Q &  "<)P  $P
M    @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( .YPU50+
M4R3(6 0  (P0   8              " @0T(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " #N<-54GZ ;\+$"  #B#   #0
M    @ &;#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( .YPU527BKL<P
M !,"   +              "  7</  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M .YPU52JQ"(6,P$  "("   /              "  6 0  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " #N<-54)!Z;HJT   #X 0  &@
M@ ' $0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #N
M<-5499!YDAD!  #/ P  $P              @ &E$@  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"  #O$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea161846-8k_abvcbio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://abvcpharma.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ea161846-8k_abvcbio.htm">ea161846-8k_abvcbio.htm</File>
    <File>abvc-20220621.xsd</File>
    <File>abvc-20220621_lab.xml</File>
    <File>abvc-20220621_pre.xml</File>
    <File>ea161846ex10-1_abvcbio.htm</File>
    <File>ea161846ex10-2_abvcbio.htm</File>
    <File>ea161846ex99-1_abvcbio.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea161846-8k_abvcbio.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ea161846-8k_abvcbio.htm"
     ]
    },
    "labelLink": {
     "local": [
      "abvc-20220621_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abvc-20220621_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "abvc-20220621.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ABVC",
   "nsuri": "http://abvcpharma.com/20220621",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea161846-8k_abvcbio.htm",
      "contextRef": "From2022-06-21to2022-06-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://abvcpharma.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea161846-8k_abvcbio.htm",
      "contextRef": "From2022-06-21to2022-06-21",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://abvcpharma.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001213900-22-033890-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-22-033890-xbrl.zip
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M;0]G@THOR+2M6H$YR,+#I>6M#Q89(-<S,L0G)L7"ZI;?<?:2T A>,D-R+\
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MU]\&1KMEYDU-:M(T*#0@SM[B%R#P4 6JU?&A-F/YO)@G'QJ7V=Q8]+1XQ.(
MWF[S3,Z@PAA\%;PSR/'MA0$-,&XR=$0$A-X F] -AR(2%:$?D I&M6A/YV?9
M(0L@B3_O[\D#X?*]@R79Y9_%CIXZSC &Q+H^>QO<'/-DKC<P" C?ZA8ZU<M0
MO0*TDL^(E56@WV0EJ*C%]OOE]4W7XI/8K#>)OU8X(V++?P%02P,$%     @
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MVW)G;_!PN[K5.:;S1"F?S^UE]+!>62;Y0MT^:3HNJ*!'3JR!^=L!"Z48&SA
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MMKKW:!"KU[NQ%BZ%=_K<&2*==NG4!W-4$&;R% UEW38:#UQJ4UT;^2T&8#U
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MF'ZIEELJFM= -M6]TO%!Z8PU6]6KJGJ^W[[%_R 4MO!? _S+4_ OG[$;[EK
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MB'[=4XF<,U@ZLEB:14XR.$3YIS,&2V3'V)!I1"""%'/^<.+MH'BJE.=A8K6
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M3"EU:ZY2CVO+5*G9V,Z\(.1A%(KQ>B:0OG[DT$-=\J0%-&UQLKS(IWI!;@_
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MG^U"X<RCF%[/PYF&Z48I C&<K<)]PZ9Q@=5SYH54#CK @]2Q%GB$,T[Q\05
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M#8SH0 05\G*(%N@"GT)9QXDN<#5SU&20&,@1S'CA[CX261-=NA&YACK1$WX
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MN+C$BB_%E3,-HNR+QJ@KD>4\DS59@"L38"4*+"-'Q7-,VIA+@>=<):M*NJ&
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MZ\/\]W;K]0X5/?XO9.%P.X*F57X8$'& BT(W)$G\5!P?_[Z.WMA0;\Z28U.
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MB8G2E#L[TLH31/*PB'(,,D^S9=UK* 0I3G/V<T^PC0CZ^4H3+@GDA9>Q6AN
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M3F@4F"81NZY,#)ML4:DQ[?9<9!N [!GQ(PR$]7O=S,*OT:R<53FEU]R'\/Y
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MQ=W$L++*,9_ES]3M[;&_C%2_#-3)=&M_ZV%<\0-"UMM<%@G:LJK[ABDU*'I
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MAW[C(?P*!/VFQ+\ 4$L! A0#%     @ [G#55/]-JE(M P  L0L  !$
M         ( !     &%B=F,M,C R,C V,C$N>'-D4$L! A0#%     @ [G#5
M5'*4Y-[^"@  @(8  !4              ( !7 ,  &%B=F,M,C R,C V,C%?
M;&%B+GAM;%!+ 0(4 Q0    ( .YPU523T7015@<  -E7   5
M  "  8T.  !A8G9C+3(P,C(P-C(Q7W!R92YX;6Q02P$"% ,4    " #N<-54
M& W\H0L9   WL   %P              @ $6%@  96$Q-C$X-#8M.&M?86)V
M8V)I;RYH=&U02P$"% ,4    " #N<-54N!:<,GH9  #/L0  &@
M    @ %6+P  96$Q-C$X-#9E>#$P+3%?86)V8V)I;RYH=&U02P$"% ,4
M" #N<-54TY@#2"LM  !,&@$ &@              @ $(20  96$Q-C$X-#9E
M>#$P+3)?86)V8V)I;RYH=&U02P$"% ,4    " #N<-54YPT"!/8*   P(0
M&@              @ %K=@  96$Q-C$X-#9E>#DY+3%?86)V8V)I;RYH=&U0
52P4&      < !P#B 0  F8$

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
